For example, someone with a $200,000 portfolio usually pays an adviser or brokerfor an asset allocation, a selection of stocks, bonds and mutual funds, andportfolio monitoring for an average of $5,000 per year, or a total of 2.5percent including fund and adviser fees, and trading commissions. E.Adviser reduces these fees by over 80 percent to $800 per year, or .4 percent-- closer to what smart investors pay. This includes the monthly subscription($9.95 per month), ETF fund fees and trading commissions. A subscriber gets asophisticated asset allocation and a globally diversified portfolio of the best,lowest cost ETFs. She also avoids bias, expensive mutual funds and highcommissions. Investors can use a fee calculator on to understand howdevastating 2 percent in excess fees is to a portfolio.
After 15 years, assumingan average annual return of 6 percent, an investor with a $200,000 portfolio whopays 2.5 percent in fees ends up with $335,000 but an investor paying only .4percent ends up with $453,000 and has 35 percent more money. Finally, sophisticated investors don`t "buy and hold." Rather they increasetheir returns by continually rebalancing their portfolios back to their targetallocations, which means taking the counter intuitive action of selling sharesof ETFs that are performing well and buying more shares of ones that have beenlagging. Until E.Adviser, rebalancing technology had only been available tosophisticated investors who could afford systems in the tens of thousands ofdollars. E.Adviser makes rebalancing easy, monitoring the portfolio 24x7 andsending a periodic email showing what to buy and sell to realign with targetpercentages.
"Investors would be well served to cut the cord, sell their mutual funds, firetheir investment advisers and use E.Adviser in order to dramatically reduce feesand take 30 minutes every quarter to maintain their portfolios through ourrebalancing technology. They`ll also have less risk because we`ll help themachieve global diversification, investing just like the wealthy," said Beck. Just as individuals started replacing their CPAs with easy-to-use and highlyavailable tax software, investors who are starting to use E.Adviser are gainingthe confidence to manage their own portfolios and actually do their owninvesting. Nearly 2000 individuals have signed up to use E.Adviser during the15-month beta period. To help investors understand these investment methodsMarketRiders also offers a free educational section on its website. Calling it"The System" this information is presented in seven simple lessons with videosand includes a Research Library with supporting articles, links and studies.
"The economic tsunami of 2008 has spawned a powerful ETF revolution and a massexodus away from mutual funds and advisers. Our customers are desperate to getcontrol of their money and trust a proven approach instead of their broker`friend` or a financial institution that may be the next bankruptcy," Tuchmanstates. "Our mission is to get millions to join the ETF revolution and investusing the smartest and most proven approach available so their portfolios growin the fastest and safest way possible." About MarketRidersMarketRiders () is an online investment services companythat gives anyone the tools, techniques and strategies to now join the ExchangeTraded Fund (ETF) revolution using strategies previously only available to eliteinvestors and large endowments like Yale and Harvard. Its E.Adviser onlineservice lets anyone easily build and manage their own ETF portfolios.MarketRiders was co-founded by Mitch Tuchman, a Harvard MBA and hedge fundinvestor, and Steve Beck, an initial investor in Baidu (NASDAQ: BIDU), to bringthe investment methods of the wealthiest Americans and most elite institutionsto everyone so their money grows in the fastest and safest way possible. Formore information visit Hot Tomato MarketingErica Zeidenberg, 925-631-0553 Copyright Business Wire 2009.
SAN DIEGO--(Business Wire)--Novocell, Inc., a stem cell engineering company, today announced that it willreceive two funding awards totaling $6.2 million from the California Institutefor Regenerative Medicine (CIRM). The grants cover development of methods fordelivery and monitoring safety of human embryonic stem cell (hESC)-derivedpancreatic cells for diabetes cell therapy. The two awards were given as part of the CIRM`s Tools & Technology and EarlyTranslational Research Awards and will be used to overcome specific bottlenecksassociated with Novocell`s innovative stem cell therapy for the treatment ofdiabetes. The deliverables generated from this work may also eventually beemployed in the development of other hESC-derived products. For thetranslational award, Novocell was ranked in the top three among all applicants. Novocell has developed and proven methods to efficiently generate pancreatic,insulin-producing cells from hESCs, demonstrating for the first time that hESCscould serve as a source of cellular therapy for diabetes.